Core Viewpoint - The company Bai Aosai Tu-B (02315) has successfully listed on the Sci-Tech Innovation Board, establishing a dual-platform listing structure of "H+A" after its previous listing on the Hong Kong Stock Exchange in September 2022, which is a significant step in enhancing its capital market presence and corporate value [1] Group 1: Stock Performance - Bai Aosai Tu-B's stock rose over 5% during trading, with a current increase of 4.15%, priced at 28.12 HKD, and a trading volume of 19.5098 million HKD [1] Group 2: Business Strategy - The company initiated the "Thousand Mice, Ten Thousand Antibodies" plan in March 2020, utilizing an "antibody shelf" model that reduces R&D time and lowers early-stage R&D uncertainties, while also improving the efficiency and success rate of clinical transformations for pharmaceutical companies [1] - The antibody business started in 2020, generating revenue of 0.41 million CNY in its first year, with revenue reaching 1.63 million CNY in the first half of 2025, reflecting a year-on-year growth of 37.8% [1] - As further molecular developments progress in clinical trials, the company's platform value is expected to increase significantly [1]
港股异动 盘中涨超5% 公司成功登陆科创板 构建A+H双平台上市格局